VRDN
NASDAQ
US
Viridian Therapeutics, Inc. - Common Stock
$18.84
▼ $-0.31
(-1.62%)
Vol 3.0M
5
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$3.0B
ROE
-52.7%
Margin
-426.6%
D/E
4.15
Beta
0.94
52W
$10–$34
Wall Street Consensus
25 analysts · Apr 20269
Strong Buy
13
Buy
3
Hold
0
Sell
0
Strong Sell
88.0%
Buy Rating
Price Chart
Similar Stocks
TYRA
Tyra Biosciences Inc
$1.4B
CLDX
Celldex Therapeutics Inc
$1.8B
AGIO
Agios Pharmaceuticals Inc
$1.6B
SLNO
Soleno Therapeutics Inc
$2.5B
STOK
Stoke Therapeutics Inc
P/E 44.2
$1.8B
CAPR
Capricor Therapeutics Inc
$1.6B
SION
Sionna Therapeutics Inc
$1.8B
VCEL
Vericel Corp
P/E 139.2
$1.8B
PVLA
Palvella Therapeutics Inc
$1.2B
Earnings
Beat rate: 100.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-1.09 | $-1.08 | +$0.01 |
| Sep 2025 | $-1.10 | $-0.34 | +$0.76 |
| Jun 2025 | $-1.03 | $-1.00 | +$0.03 |
| Mar 2025 | $-0.99 | $-0.87 | +$0.12 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -55.1% | -55.1% | -55.1% | -55.1% | -52.6% | -52.6% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -134313.3% | -112806.9% | -112806.9% | -112806.9% | -426.6% | -426.6% |
| Gross Margin | — | 2.4% | 2.4% | 2.4% | 2.4% | 2.4% |
| D/E Ratio | 4.04 | 4.04 | 4.04 | 4.04 | 4.15 | 4.15 |
| Current Ratio | 11.01 | 11.01 | 11.01 | 11.01 | 11.28 | 11.28 |
Key Ratios
ROA (TTM)
-47.1%
P/S (TTM)
41.96
P/B
2.3
EPS (TTM)
$-3.72
CF/Share
$-5.09
Rev Growth 3Y
-53.3%
52W High
$34.04
52W Low
$9.90
$9.90
52-Week Range
$34.04
How does VRDN compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
VRDN valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
42.0
▲
227%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
2.3
▼
8%
below
peers
(2.5)
vs Peers
vs Industry
Fair value
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
VRDN profitability vs Biotechnology peers
ROE
-52.7%
▲
22%
above
peers
(-67.3%)
vs Peers
vs Industry
Below avg
Net margin
-426.6%
▼
49%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
2.4%
▼
97%
below
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-47.1%
▼
1%
below
peers
(-46.7%)
vs Peers
vs Industry
In line
VRDN financial health vs Biotechnology peers
D/E ratio
4.2
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
11.3
▲
154%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
0.9
▼
3%
below
peers
(1.0)
vs Peers
vs Industry
Less volatile
VRDN fundamentals radar
VRDN
Peer median
Industry
VRDN profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio